Introduction: The Impact of Ibrutinib in Oncology and the Value of a Global Buyers List Ibrutinib, a breakthrough Bruton’s tyrosine kinase (BTK) inhibitor marketed under the brand name Imbruvica, has revolutionized the treatment of B-cell malignancies. Approved by regulatory bodies worldwide for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and several other non-Hodgkin lymphomas (NHL), it targets a critical enzyme driving cancer cell growth, offering prolonged remission and improved survival rates. As global cancer incidence rises—with the WHO estimating 28.7 million new cases in 2040—demand for precision therapies like ibrutinib continues to surge. For pharmaceutical suppliers, manufacturers, and distributors, accessing a reliable Ibrutinib Global Buyers List is essential to…